期刊文献+

计算机编程建立肝脏移植患者他克莫司的有效血药浓度范围 被引量:4

Establishing of effective blood drug concentration range of tacrolimus for liver transplantation patients by computer program
在线阅读 下载PDF
导出
摘要 目的 :为临床合理化使用免疫抑制剂他克莫司 (FK5 0 6 )提供理论依据 ,建立适合中国人肝脏移植受者FK5 0 6的有效血药浓度范围。方法 :用VISUALBASIC 6 .0开发程序 ;程序对用微粒子酶免分析法 (MEIA)测定全血FK5 0 6的血药浓度数据进行处理。结果 :肝脏移植术后 1mo内FK5 0 6理想有效血药浓度范围为 7~ 14 μg·L-1。结论 :该程序是开展治疗药物监测工作非常实用的工具 ,按程序所推荐浓度范围调整给药方案 ,既可获得满意的免疫抑制效果 ,又能减少排斥反应和FK5 0 AIM: To establish effective blood drug concentration range of tacrolimuns for Chinese liver transplantation recipients, in order to provide theoretical basis for reasonable use of the immuneosuppressive agent, tacrolimus. METHODS: The program was developed by VISUAL BASIC 6.0. The data of blood drug concentration, determinated by MEIA, was processed by the program. RESULTS: The effective blood drug concentration range of the patients in the first month of their liver transplantation was 7-14 μg·L -1. CONCLUSION: The program was a very applied tool to carry out blood drug concentration monitoring .The medication project adjusted by this reference concentration range of tacrolimus can achieve the satisfied immuneosuppressive result, and reduce rejection and tacrolimus toxicity.
作者 向莉 李盾
出处 《中国临床药学杂志》 CAS 2004年第5期284-287,共4页 Chinese Journal of Clinical Pharmacy
基金 深圳市科技局基金资助项目 (编号 :2 0 0 0 0 60 17 2 0 0 2 0 40 48)
关键词 血药浓度 FK506 肝脏移植术 他克莫司 患者 治疗药物监测 微粒子酶免分析法 范围 结论 开发程序 liver transplantation tacrolimus effective blood drug concentration range program
  • 相关文献

参考文献4

二级参考文献16

  • 1[1]Grenier FC, Luczkiw J, Bergmann M et al. A whole blood FK506 assay for the IMx analyzer. Transplant Proc,1991,23:2745
  • 2[2]Tanaka H, Kuroda A, Marusawa H et al. Physicochemical properties of FK506,a novel imrmmosuppressant isolated from streptomyces tsukubaensis. Transplant Proc, 1987b, 19:11
  • 3[3]Takahara S, Takano Y, Montabarrik A et al. Blood level monitoring of FK506 on kidney transplant recipients. Nippon Hinyokika Gakkai Zasshi,1993,84(10): 1857
  • 4[4]Laskow DA, Vincenti F, Neylan JF et al. An open-label, concentrationranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. Transplantation, 1996,62(7) :900
  • 5[5]Shaw LM. Kaplan B, Brayman et al. Prospe-ctive investigations of concentration-clinical for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. Clin Chem, 1998,44(2) :381
  • 6[1]Abu Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver[J]. Transplantation, 1991, 52(1):71-7.
  • 7[2]Jain AB, Venkataramarian R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations[J]. Transplant Proc, 1990, 22(supp1):57-9.
  • 8[3]Boswell GW, Bekersky, Fay J, et al. Tacrolimus pharmacokinetics in BMT patients[J]. Bone Marrow Transplant, 1998, 21:23-8.
  • 9[4]van Hooff JP, Christians MH. Use of tacrolimus in renal transplantation[J]. Transplant Proc, 1999, 31:3298-9.
  • 10[5]Tanabe K, Ishikawa N, Tokumoto T, et al. Long-term results of living kidney transplantation under tacrolimus immunosuppression: a single-center experience[J]. Transplant Proc, 1998, 30:1224~6.

共引文献32

同被引文献33

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部